Vertex Pharmaceuticals has completed submission of a rolling Biologics License Application to the FDA for povetacicept, seeking potential accelerated approval to treat immunoglobulin A nephropathy in adults. Vertex used a priority review voucher and therefore expects the FDA’s review to be expedited to six months from acceptance versus the typical ten-month review.
Vertex Pharmaceuticals Inc filing shows The Vanguard Group reports 0 shares beneficially owned of Common Stock, representing 0% following an internal realignment.
The amendment states certain Vanguard subsidiaries will report beneficial ownership separately in reliance on SEC Release No. 34-39538 and that The Vanguard Group, Inc. "no longer has, or is deemed to have, beneficial ownership" of securities held by those subsidiaries. The filing is signed by Ashley Grim on 03/27/2026.
Carmen R. Bozic reported sales of Common stock via Form 144. The filing lists sales dated 02/27/2026 and 03/13/2026 tied to the instrument identifier 2329. The excerpt also shows Restricted Stock Vesting entries dated 02/24/2025 (1687) and 02/26/2025 (642) labeled as compensation.
Vertex Pharmaceuticals executive Carmen Bozic reported an open-market sale of company stock. On March 13, 2026, Dr. Bozic sold 2,329 shares of Vertex common stock at a price of $481.79 per share, as part of routine portfolio activity.
After this transaction, Dr. Bozic directly held 35,405 shares of Vertex common stock, indicating she retains a substantial ownership stake. The sale was carried out under a pre-established Rule 10b5-1 trading plan, meaning it was scheduled in advance under company-approved guidelines rather than timed opportunistically.
Vertex Pharmaceuticals executive Duncan McKechnie sold 2,633 shares of common stock in an open-market transaction. The sale occurred on March 11, 2026, at an average price of $498.42 per share. After the sale, he directly held 12,489 Vertex shares.
The transaction was made under a company-approved Rule 10b5-1 trading plan that Mr. McKechnie entered into on November 25, 2025, indicating the sale was pre-scheduled rather than opportunistic.
Carmen R. Bozic submitted a Form 144 notice to sell Common Stock. The filing lists Fidelity Brokerage Services LLC as the broker and references restricted stock vesting dated 02/26/2025. The form shows a sale recorded on 02/27/2026 and is dated 03/13/2026.
Issuer reported proposed sales of Common Stock via Form 144 by Duncan J. McKechnie. The filing lists two proposed dispositions: $2,394,365.00 for 4,910 shares on 02/25/2026 and $1,158,306.10 for 2,437 shares on 03/04/2026.
The filing also records restricted stock vesting events dated 02/10/2026 and 02/17/2026, including a vesting of 612 compensation shares on 02/17/2026. The entries identify Fidelity Brokerage Services LLC and NASDAQ as custodial/market references.
Vertex Pharmaceuticals executive reports planned share sale
Vertex Pharmaceuticals EVP and Chief Commercial Officer Duncan McKechnie sold 2,437 shares of common stock in an open-market transaction at $475.30 per share. After this sale, he directly holds 15,122 shares. The trade was made under a company-approved Rule 10b5-1 trading plan entered into on 11/25/2025.
Vertex Pharmaceuticals executive Joy Liu sold shares under a pre‑planned program. On March 2, 2026, she completed an open-market sale of 892 shares of Vertex common stock at $495.96 per share. After this transaction, she directly held 22,811 Vertex shares. The sale was made under a company-approved Rule 10b5‑1 trading plan entered into on November 25, 2025.
Issuer reports proposed insider sale and recent transactions. The filing shows 2,437 restricted common shares that vested on 02/13/2026 as compensation. It also discloses a reported sale of 4,910 common shares on 02/25/2026 by Duncan J. McKechnie for $2,394,365.00.
The notice was submitted under Form 144 and lists Fidelity Brokerage Services LLC as the broker. Timing and aggregated proceeds for any proposed disposition are limited to the amounts shown in the filing.